A|B|C|D|E|F|G|H|I|J|K|L|M|N|O|P|Q|R|S|T|U|V|W|X|Y|Z|ALL

  检 索： 期刊名称 ISSN         高级检索

期刊名称：MOLECULAR THERAPY-NUCLEIC ACIDS ISSN： 2162-2531 出版频率： Quarterly 出版社： CELL PRESS, 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, USA, MA, 02139   出版社网址： http://www.nature.com/ 期刊网址： http://www.nature.com/mtna/index.html 影响因子： 8.886 主题范畴： MEDICINE, RESEARCH & EXPERIMENTAL 变更情况： Newly Added by 2014 期刊简介(About the journal)    投稿须知(Instructions to Authors)    编辑部信息(Editorial Board)    About the journal Aims and Scope Molecular Therapy — Nucleic Acids is an international, open-access journal publishing top-quality basic, translational, and clinical research in the broad fields of nucleic acid-based therapeutics to treat and/or correct genetic and acquired disease. As an official journal of the American Society of Gene & Cell Therapy, Molecular Therapy — Nucleic Acids will build upon the success of Molecular Therapy in publishing important peer-reviewed research and cutting-edge reviews and commentaries targeted to advances in gene- and oligonucleotide-based therapies. Subject areas include, but are not limited to: development of therapeutics based on nucleic acids and their derivatives, vector development and design for the delivery of RNA based therapeutics, applications of gene modifying agents including triplex forming oligonucleotides and enzymes such as Zn finger nucleases, pre-clinical target validation, safety/efficacy studies, and clinical trials. Other key topics include: Applications of DNA based oligonucleotides and their derivatives Gene vectors for delivery of RNA-based therapies Development of nanoparticles and other delivery agents siRNAs, shRNAs, and miRNAs Aptamers, ribozymes, and DNAzymes Peptide nucleic acids Gene modifying approaches including enzymes, triplex forming nucleic acids, and other approaches Development of new nucleic acid chemistries for altering gene expression Mechanisms of gene and nucleic acid transfer/transfection Vector trafficking and biodistribution Molecular Therapy — Nucleic Acids is a peer-reviewed, open access, online only journal that publishes Original Articles, Reviews, Commentaries, Letters to the Editor, and Editorials. Top of page Abstracted/indexed in Pubmed Crossref British Lib Nature Asia Chemical Abstracts Ebsco Infotrieve Current Contents/Thomson Reuters Pubmed Central Elsevier/Excerpta Medica Swetsnet University Of Toronto Top of page ISSN The ISSN (online) number for Molecular Therapy — Nucleic Acids is 2162-2531. Instructions to Authors Did you know? That Molecular Therapy — Nucleic Acids is an online, open access journal That the millions of users of nature.com can now sign up for an e-mail copy of the table of contents for the Molecular Therapy — Nucleic Acids issue in which your article is published Top of page Submitting an article To read about how to prepare your article, please click on Instructions for Authors. If you are ready to submit an article please click on Online Submission. Top of page Benefits of publishing with NPG Molecular Therapy — Nucleic Acids is one of two official journals of the American Society of Gene & Cell Therapy and is a sibling journal to the successful title, Molecular Therapy. The journal is committed to publishing high quality, independently peer-reviewed research and review material. The journal is published by Nature Publishing Group (NPG), which uses pioneering technologies, innovative formats and world-class production to provide premium information for scientific researchers in the public and private sectors, government agencies and educators. A key strength of NPG is its close relationship with the scientific community. By working closely with scientists, listening to what they say, and always placing emphasis on quality rather than quantity, NPG is the leading scientific publisher at finding innovative solutions to scientists' information needs, both for the Nature-branded publications and those published on behalf of society partners. Molecular Therapy — Nucleic Acids provides an author with a wide range of benefits: Open access As an open access journal, Molecular Therapy — Nucleic Acids content is freely available to all researchers worldwide ensuring maximum dissemination. Content is published online on a weekly basis to provide timely communication to the community and keep publication times to a minimum. Authors of accepted manuscripts are charged an article-processing fee dependent upon article type and licence chosen. Please see the journal's Instructions to Authors for full price listing. Creative Commons license Molecular Therapy — Nucleic Acids articles are published either under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 Unported Licence, a Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported Licence, or a Creative Commons Attribution 3.0 Unported Licence at the free choice of the authors. The latter licence permits derivative works even commercially. More information about licence choice can be found on the Open Access page. Online submission - reducing publication times The new electronic manuscript submission website for Molecular Therapy — Nucleic Acids is available at: http://mts-mtna.nature.com/ Quality Authors who choose to publish in any NPG journal can be assured that its staff's publishing, editorial and production skills are committed to maintaining the highest possible quality and standards. Regular free e-mail alerts Content published in Molecular Therapy — Nucleic Acids has the potential to reach scientists around the world who have signed up for the journal's free Table of Contents e-alerts, ensuring additional exposure to authors. These e-alerts will allow recipients to click through to the full article. Focused subject areas on nature.com From immunology to physics, genetics to materials, subject-specific areas provide a focused environment for readers, providing a monthly updated focus for a particular field. So readers of all NPG's journals, including Molecular Therapy, Nature Medicine, Nature Genetics, Nature Biotechnology, and more will be able to also easily keep up-to-date with the latest research being published in Molecular Therapy — Nucleic Acids. Abstracting and indexing Extensive reference linking via services such as Crossref and DOI numbers provide seamless online linking between articles and databases. Media coverage The Nature News Service provides information about exceptionally interesting papers published throughout NPG. More than 2,000 journalists and media organizations worldwide subscribe to the press service, ensuring that papers receive maximum exposure in the world's most important media channels including newspapers, magazines, radio and television. Editorial Board Editor-in-Chief John Rossi, PhD Department of Molecular and Cellular Biology Beckman Research Institute of the City of Hope 1450 East Duarte Road Duarte, CA 91010 Editor Robert Frederickson, PhD Section Heads Aptamers Vittorio de Franciscis: Institute for Endocrinology and Oncology, Naples, Italy Paloma Giangrande: University of Iowa, Iowa City, Iowa, USA Editorial Board Veenu Aishwarya: Aum LifeTech, Philadelphia, PA, USA Akin Akinc: Alnylam Pharmaceuticals, Cambridge, MA, USA Daniel Anderson: Massachusetts Institute of Technology, Cambridge, MA, USA Mark Behlke: Integrated DNA Technologies, Coralville, IA, USA Jean-Paul Behr: Louis Pasteur University, Illkirch, France Ben Berkhout: University of Amsterdam, Amsterdam, Netherlands Toni Cathomen: University Medical Center Freiburg Germany, Hannover, Germany David Corey: UT Southwestern, Dallas, Texas Beverly Davidson: Universtiy of Iowa, Iowa City, IA, USA Mark Davis: California Institute of Technology, Pasadena, CA, USA Michael Gait: Medical Research Council, Cambridge, UK Eli Gilboa: University of Miami,Miami, FL, USA Peter Glazer: Yale University School of Medicine, New Haven, CT, USA Dirk Grimm: University of Heidelberg, Heidelberg, Germany Dieter Gruenert: University of California, San Francisco, San Francisco, CA, USA Leaf Huang: University of North Carolina, Chapel Hill, NC, USA Zoltan Ivics: Paul Ehrlich Institute, Langen, Germany Mark Kay: Stanford University School of Medicine, Stanford, CA, USA Jorgen Kjems: Aarhus University, Aarhus, Denmark Ryszard Kole: AVI Biopharma, Bothell, WA, USA Dong-ki Lee: Sungkyunkwan University, Suwon, Republic of Korea Seong-Wook Lee: Dankook University, Yongin, Republic of Korea Judy Lieberman: Harvard Medical School, Boston, MA, USA Dexi Liu: University of Georgia College of Pharmacy, Athens, GA, USA Ian Maclachlan: Tekmira Pharmaceuticals Corp., Burnaby, Canada Brett Monia: Isis Pharmaceuticals, Carlsbad, CA, USA Kevin Morris: Scripps, La Jolla, CA, USA Takahiro Ochiya: National Cancer Center Research Institute, Tokyo, Japan Eirini Papapetrou: University of Washington, Seattle, WA, USA Matthew Porteus: Stanford Medical Center, Stanford, CA, USA Kevin Rice: University of Iowa, Iowa City, IA, USA Shigeki Sasaki: Kyushu University, Fukuoka, Japan David Schaffer: University of California at Berkeley, Berkeley, CA, USA Claes Wahlestedt: University of Miami, Miami, Florida, USA Marco Weinberg: University of the Witwatersrand, Johannesburg, South Africa Steve Wilton: University of Western Australia, Nedlands, Australia Matthew Wood: University of Oxford, Oxford, UK Journal contact details Molecular Therapy — Nucleic Acids 710 Summit Avenue East Seattle, WA 98102 Phone: +1 206 724 7760 Email: mtna@molther.org Journal website: http://www.nature.com/mtna/ Submission site: http://mts-mtna.nature.com/ ABOUT THE EDITORS Editor-in-Chief John Rossi, PhD Dr. Rossi received his doctorate in microbial genetics from the University of Connecticut in Storrs. For postdoctoral training Dr. Rossi went to Brown University Medical School in Providence, Rhode Island where he trained under Dr. Arthur Landy studying the genomic structure, organization and expression of two gene clusters encoding tRNA-tyrosine in E. coli. This research led to the first observation that a tRNA gene cluster was co-transcribed with and subsequently processed from an mRNA. In 1980 Dr. Rossi moved to the Department of Molecular Genetics at the City of Hope in Duarte, California. Dr. Rossi's laboratory began to develop and test the idea of utilizing catalytic RNAs or ribozymes for inhibition of HIV infection. This research program has led to two clinical trials in which ribozyme genes have been transduced into hematopoietic stem cells for autologous transplant in HIV infected individuals. Work in the laboratory continues to focus upon enhancing the intracellular efficacy of ribozymes and RNA decoys via RNA trafficking and target co-localization approaches. This program has led to a first of its kind hematopoietic stem cell clinical trial using a triple gene therapy approach in AIDS/lymphoma patients. At present a large percentage of the research effort of the lab is focused upon the biology and utilization of small interfering RNAs, or siRNA and the evolution of aptamers for targeted siRNA delivery. Importantly, Dr. Rossi has served on the Editorial Board of Molecular Therapy since its inception and is now Deputy Editor for the section on Oligonucleotide Therapy. Dr. Rossi previously served as co-editor in chief of Oligonucleotides from 2006-11. Dr. Rossi also serves on the board of the following journals: Antisense Research and Development, Cancer Gene Therapy, Biotechnology Journal, Journal of Biological Chemistry, BioTechniques, BMC Open biotechnology, Silence, PLoS and Human Gene Therapy. Dr. Rossi is also a regular reviewer and contributor to many high impact journals, including PNAS, Cell, Cell Host and Microbe, Nature, Nature Biotechnology, Nature Genetics, Nature Medicine, Nature Nanotechnology, EMBO Journal, EMBO Reports, EMBO Molecular Medicine, Science Translational Medicine, Science, Nucleic Acids Research, RNA, Gene Therapy, Nature Structural and Molecular Biology, Nature Chemical Biology, and others.   Editor Robert M. Frederickson, PhD Rob Frederickson received his doctorate training in virology and biochemistry at McGill University in Montreal, Canada, followed by post-doctoral work in the Department of Medical Genetics at the University of Washington. Dr. Frederickson has over 17 years of experience as a science editor and writer, beginning with a stint at Nature magazine in London. He has served as Research Editor at Nature Biotechnology and Senior Editor at Nature Medicine. Dr. Frederickson is now entering his 10th year of service as the Editor of Molecular Therapy. Dr. Frederickson has written numerous articles and contributes the regular In this Issue and Research Highlights features in Molecular Therapy.